These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 15336224)

  • 1. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.
    Ahmed AO; van Leeuwen W; Fahal A; van de Sande W; Verbrugh H; van Belkum A
    Lancet Infect Dis; 2004 Sep; 4(9):566-74. PubMed ID: 15336224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Madurella mycetomatis infection of the buttock in an Eritrean refugee in Switzerland: a case report.
    Mekoguem C; Triboulet C; Gouveia A
    J Med Case Rep; 2019 Feb; 13(1):32. PubMed ID: 30755254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against
    Ma J; Eadie K; Schippers M; Fahal A; Laleu B; Verbon A; van de Sande WWJ
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma.
    Konings M; Eadie K; Lim W; Fahal AH; Mouton J; Tesse N; van de Sande WWJ
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009488. PubMed ID: 34106933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Madurella mycetomatis infection of the foot: a case report of a neglected tropical disease in a non-endemic region.
    Karrakchou B; Boubnane I; Senouci K; Hassam B
    BMC Dermatol; 2020 Jan; 20(1):1. PubMed ID: 31918687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of a novel diagnostic PCR for Madurella mycetomatis using a comparative genome approach.
    Lim W; Siddig E; Eadie K; Nyuykonge B; Ahmed S; Fahal A; Verbon A; Smit S; van de Sande WW
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008897. PubMed ID: 33326425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
    van de Sande WW; Fahal AH; Bakker-Woudenberg IA; van Belkum A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2738-40. PubMed ID: 20350944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VNTR confirms the heterogeneity of Madurella mycetomatis and is a promising typing tool for this mycetoma causing agent.
    Lim W; Eadie K; Horst-Kreft D; Ahmed SA; Fahal AH; van de Sande WWJ
    Med Mycol; 2019 Jun; 57(4):434-440. PubMed ID: 30085253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Madurella mycetomatis grains within a eumycetoma lesion are clonal.
    Nyuykonge B; Siddig EE; Konings M; Bakhiet S; Verbon A; Klaassen CHW; Fahal AH; van de Sande WWJ
    Med Mycol; 2022 Jul; 60(7):. PubMed ID: 35833294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
    Kloezen W; Meis JF; Curfs-Breuker I; Fahal AH; van de Sande WW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6054-6. PubMed ID: 22964246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
    van de Sande WWJ; Fahal AH
    Clin Microbiol Rev; 2024 Jun; 37(2):e0003423. PubMed ID: 38690871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycetoma caused by Madurella mycetomatis: a completely neglected medico-social dilemma.
    van Belkum A; Fahal A; van de Sande WW
    Adv Exp Med Biol; 2013; 764():179-89. PubMed ID: 23654067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis.
    Ma J; Todd M; van de Sande WWJ; Biersack B
    Chem Biodivers; 2023 May; 20(5):e202300151. PubMed ID: 37067830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.
    Elfadil H; Fahal A; Kloezen W; Ahmed EM; van de Sande W
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003488. PubMed ID: 25768115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.
    Nyuykonge B; Siddig EE; Mhmoud NA; Nyaoke BA; Zijlstra EE; Verbon A; Bakhiet S; Fahal AH; van de Sande WWJ
    Mycoses; 2022 Dec; 65(12):1170-1178. PubMed ID: 36005544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
    Lim W; Konings M; Parel F; Eadie K; Strepis N; Fahal A; Verbon A; van de Sande WWJ
    Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35064672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.
    Elkheir LYM; Haroun R; Mohamed MA; Fahal AH
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008307. PubMed ID: 32853199
    [No Abstract]   [Full Text] [Related]  

  • 18. A Madurella mycetomatis Grain Model in Galleria mellonella Larvae.
    Kloezen W; van Helvert-van Poppel M; Fahal AH; van de Sande WW
    PLoS Negl Trop Dis; 2015; 9(7):e0003926. PubMed ID: 26173126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active matrix metalloprotease-9 is associated with the collagen capsule surrounding the Madurella mycetomatis grain in mycetoma.
    Geneugelijk K; Kloezen W; Fahal AH; van de Sande WW
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2754. PubMed ID: 24675764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sandalwood Oils of Different Origins Are Active In Vitro against
    Abd Algaffar SO; Seegers S; Satyal P; Setzer WN; Schmidt TJ; Khalid SA
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.